We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Syros Pharmaceuticals Inc
18 own
34 watching
Current Price
$0
$0.15
(2.88%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
103.55M
52-Week High
18.1
52-Week Low
3.02
Average Volume
0.06M
Dividend Yield
--
P/E Ratio
--
Market Capitalization103.55M52-Week High18.152-Week Low3.02Average Volume0.06MDividend Yield--P/E Ratio--What does the Syros Pharmaceuticals Inc do?
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Read More
How much money does Syros Pharmaceuticals Inc make?
News & Events about Syros Pharmaceuticals Inc.
Business Wire
8days ago
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene...
Ticker Report
22days ago
Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS Get Rating) have earned a consensus rating of Moderate Buy from the six analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have ...
Business Wire
25days ago
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023. We are entering 2023 with a singular focus on...
Business Wire
1month ago
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients...
Business Wire
1month ago
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha (RAR) agonist...
Frequently Asked Questions
Frequently Asked Questions
What is Syros Pharmaceuticals Inc share price today?
Can Indians buy Syros Pharmaceuticals Inc shares?
How can I buy Syros Pharmaceuticals Inc shares from India?
Can Fractional shares of Syros Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Syros Pharmaceuticals Inc stocks?
What is today’s traded volume of Syros Pharmaceuticals Inc?
What is today’s market capitalisation of Syros Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Syros Pharmaceuticals Inc?
What percentage is Syros Pharmaceuticals Inc down from its 52-Week High?
What percentage is Syros Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$0
$0.15
(2.88%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.